FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077422669> ?p ?o ?g. }

• W2077422669 endingPage "312" @default.
• W2077422669 startingPage "308" @default.
• W2077422669 abstract "Objectives Approximately 50% of ovarian cancers have elevated levels of epidermal growth factor receptor (EGFR) which correlates with a poor prognosis. Preclinical evidence suggests that EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib (OSI-774), may potentiate the anti-tumour effects of cytotoxic agents, including carboplatin. Blocking EGFR could thus potentially reverse drug resistance. The primary objective of the study was to assess the response rate to the addition of erlotinib in patients with recurrent ovarian cancer who were receiving carboplatin. Methods Patients enrolled on this study had either local or advanced recurrent ovarian cancer with measurable disease. They may have had up to 2 prior chemotherapy regimens, one of which must have contained platinum, and they must have responded to prior platinum therapy. Patients were stratified by platinum sensitivity and were treated with erlotinib 150 mg daily on a continuous dosing schedule, and carboplatin at an AUC of 5 every 21 days. Results Fifty patients with recurrent ovarian cancer entered the study, 33 in the platinum-sensitive arm and 17 in the platinum-resistant arm. Of patients evaluable for response, there were 14 partial responses (PR) of 30 evaluable for response (57% objective response rate (ORR)) in the platinum-sensitive arm, and 1 PR of 14 evaluable for response (7% ORR) in the platinum-resistant arm. Conclusions The combination of erlotinib and carboplatin was active in patients with platinum-sensitive disease, but not in platinum-resistant disease. The toxicities seen were those expected with carboplatin and erlotinib." @default.
• W2077422669 created "2016-06-24" @default.
• W2077422669 creator A5015476569 @default.
• W2077422669 creator A5015545810 @default.
• W2077422669 creator A5018001559 @default.
• W2077422669 creator A5026047065 @default.
• W2077422669 creator A5044291041 @default.
• W2077422669 creator A5046515596 @default.
• W2077422669 creator A5064421707 @default.
• W2077422669 creator A5073362806 @default.
• W2077422669 date "2010-09-01" @default.
• W2077422669 modified "2023-09-23" @default.
• W2077422669 title "A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149)" @default.
• W2077422669 cites W141627170 @default.
• W2077422669 cites W1898738795 @default.
• W2077422669 cites W1965346067 @default.
• W2077422669 cites W1967119242 @default.
• W2077422669 cites W1968807523 @default.
• W2077422669 cites W1970539996 @default.
• W2077422669 cites W1999784741 @default.
• W2077422669 cites W2006621710 @default.
• W2077422669 cites W2010174111 @default.
• W2077422669 cites W2013492426 @default.
• W2077422669 cites W2013498672 @default.
• W2077422669 cites W2018358158 @default.
• W2077422669 cites W2026175788 @default.
• W2077422669 cites W2030437687 @default.
• W2077422669 cites W2032077983 @default.
• W2077422669 cites W2034642746 @default.
• W2077422669 cites W2046052085 @default.
• W2077422669 cites W2046592303 @default.
• W2077422669 cites W2063953472 @default.
• W2077422669 cites W2064047613 @default.
• W2077422669 cites W2064065563 @default.
• W2077422669 cites W2065882404 @default.
• W2077422669 cites W2075668200 @default.
• W2077422669 cites W2092931003 @default.
• W2077422669 cites W2094062129 @default.
• W2077422669 cites W2095879193 @default.
• W2077422669 cites W2097105130 @default.
• W2077422669 cites W2104344253 @default.
• W2077422669 cites W2105453387 @default.
• W2077422669 cites W2105511717 @default.
• W2077422669 cites W2106538825 @default.
• W2077422669 cites W2108187449 @default.
• W2077422669 cites W2116622068 @default.
• W2077422669 cites W2116996913 @default.
• W2077422669 cites W2117729836 @default.
• W2077422669 cites W2120085428 @default.
• W2077422669 cites W2130941707 @default.
• W2077422669 cites W2139248078 @default.
• W2077422669 cites W2148011209 @default.
• W2077422669 cites W2152419134 @default.
• W2077422669 cites W2328421677 @default.
• W2077422669 doi "https://doi.org/10.1016/j.ygyno.2010.05.005" @default.
• W2077422669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20646751" @default.
• W2077422669 hasPublicationYear "2010" @default.
• W2077422669 type Work @default.
• W2077422669 sameAs 2077422669 @default.
• W2077422669 citedByCount "57" @default.
• W2077422669 countsByYear W20774226692012 @default.
• W2077422669 countsByYear W20774226692013 @default.
• W2077422669 countsByYear W20774226692014 @default.
• W2077422669 countsByYear W20774226692015 @default.
• W2077422669 countsByYear W20774226692016 @default.
• W2077422669 countsByYear W20774226692017 @default.
• W2077422669 countsByYear W20774226692018 @default.
• W2077422669 countsByYear W20774226692019 @default.
• W2077422669 countsByYear W20774226692020 @default.
• W2077422669 countsByYear W20774226692021 @default.
• W2077422669 countsByYear W20774226692022 @default.
• W2077422669 countsByYear W20774226692023 @default.
• W2077422669 crossrefType "journal-article" @default.
• W2077422669 hasAuthorship W2077422669A5015476569 @default.
• W2077422669 hasAuthorship W2077422669A5015545810 @default.
• W2077422669 hasAuthorship W2077422669A5018001559 @default.
• W2077422669 hasAuthorship W2077422669A5026047065 @default.
• W2077422669 hasAuthorship W2077422669A5044291041 @default.
• W2077422669 hasAuthorship W2077422669A5046515596 @default.
• W2077422669 hasAuthorship W2077422669A5064421707 @default.
• W2077422669 hasAuthorship W2077422669A5073362806 @default.
• W2077422669 hasConcept C121608353 @default.
• W2077422669 hasConcept C126322002 @default.
• W2077422669 hasConcept C143998085 @default.
• W2077422669 hasConcept C2776694085 @default.
• W2077422669 hasConcept C2778087573 @default.
• W2077422669 hasConcept C2778239845 @default.
• W2077422669 hasConcept C2778822529 @default.
• W2077422669 hasConcept C2779438470 @default.
• W2077422669 hasConcept C2780427987 @default.
• W2077422669 hasConcept C2781451048 @default.
• W2077422669 hasConcept C31760486 @default.
• W2077422669 hasConcept C71924100 @default.
• W2077422669 hasConceptScore W2077422669C121608353 @default.
• W2077422669 hasConceptScore W2077422669C126322002 @default.
• W2077422669 hasConceptScore W2077422669C143998085 @default.
• W2077422669 hasConceptScore W2077422669C2776694085 @default.
• W2077422669 hasConceptScore W2077422669C2778087573 @default.

• next